Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$54,836 | -$62,255 | -$94,660 | -$122,725 |
| Dep. & Amort. | $12,625 | $13,160 | $12,668 | $1,879 |
| Deferred Tax | -$2,268 | -$1,249 | -$1,424 | -$1,424 |
| Stock-Based Comp. | $18,363 | $10,716 | $12,160 | $11,381 |
| Change in WC | -$8,820 | -$6,294 | -$35,150 | $11,854 |
| Other Non-Cash | -$2,045 | -$1,101 | $3,515 | $3,500 |
| Operating Cash Flow | -$36,981 | -$47,023 | -$102,891 | -$102,891 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$868 | -$2,263 | -$524 | -$524 |
| Net Acquisitions | $0 | $0 | $0 | $38,469 |
| Inv. Purchases | -$34,485 | -$43,741 | $0 | -$43,020 |
| Inv. Sales/Matur. | $40,236 | $40,000 | $34,985 | $34,985 |
| Other Inv. Act. | $0 | $0 | $0 | $4,551 |
| Investing Cash Flow | $4,883 | -$6,004 | $34,461 | $34,461 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $38,169 | $0 | $102,718 | $0 |
| Stock Issued | $0 | $581 | $30,000 | $27,000 |
| Stock Repurch. | -$3,734 | -$1,009 | -$468 | -$534 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $1,733 | -$604 | -$4,777 | $0 |
| Financing Cash Flow | $36,168 | -$1,613 | $127,473 | $27,247 |
| Forex Effect | $0 | $0 | -$4,348 | -$3 |
| Net Chg. in Cash | $4,070 | -$54,640 | $59,043 | $59,043 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $71,674 | $126,314 | $67,271 | $67,271 |
| End Cash | $75,744 | $71,674 | $126,314 | $126,314 |
| Free Cash Flow | -$37,849 | -$49,286 | -$103,415 | -$103,415 |